David Aboulafia
Overview
Explore the profile of David Aboulafia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennett C, Martin L, Watson G, Rosen S, Aboulafia D
Eur J Intern Med
. 2025 Mar;
PMID: 40089406
No abstract available.
2.
Atkinson T, Lynch K, Vera J, Olivares N, Webb A, Diamond L, et al.
J Patient Rep Outcomes
. 2022 Oct;
6(1):108.
PMID: 36219358
Objectives: The Anal Cancer High-grade squamous intraepithelial lesions (HSIL) Outcomes Research (ANCHOR) Health-Related Symptom Index (A-HRSI) is a 25-item measure that assesses physical symptoms and impacts, and psychological symptoms. To...
3.
Reid E, Shimabukuro K, Moore P, Ambinder R, Bui J, Han S, et al.
Clin Cancer Res
. 2022 Mar;
28(12):2646-2656.
PMID: 35247913
Purpose: Kaposi sarcoma (KS), an endothelial cell tumor associated with KS herpesvirus (KSHV), remains among the most common malignancies occurring with HIV infection (HIV-KS). As an oral anti-inflammatory, antiangiogenic, and...
4.
Bennett C, Hoque S, Olivieri N, Taylor M, Aboulafia D, Lubaczewski C, et al.
EClinicalMedicine
. 2021 Feb;
31:100693.
PMID: 33554084
Background: Adverse drug/device reactions (ADRs) can result in severe patient harm. We define very serious ADRs as being associated with severe toxicity, as measured on the Common Toxicity Criteria Adverse...
5.
Ramos J, Sparano J, Chadburn A, Reid E, Ambinder R, Siegel E, et al.
Blood
. 2020 May;
136(11):1284-1297.
PMID: 32430507
EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) is a preferred regimen for HIV-non-Hodgkin lymphomas (HIV-NHLs), which are frequently Epstein-Barr virus (EBV) positive or human herpesvirus type-8 (HHV-8) positive. The histone...
6.
Sparano J, Lee J, Kaplan L, Ramos J, Ambinder R, Wachsman W, et al.
Haematologica
. 2020 Feb;
106(3):730-735.
PMID: 32107337
Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical...
7.
Reid E, Suazo A, Lensing S, Dittmer D, Ambinder R, Maldarelli F, et al.
Clin Cancer Res
. 2019 Oct;
26(3):558-565.
PMID: 31624104
Purpose: AIDS-related Kaposi sarcoma is often incompletely controlled, requiring serial therapies. Kaposi sarcoma herpesvirus (KSHV) induces transformation of endothelial cells, where it resides in a predominately latent state. We hypothesized...
8.
Reid E, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al.
Blood Adv
. 2018 Dec;
2(24):3618-3626.
PMID: 30573564
HIV-associated lymphomas (HALs) have high rates of latent infection by gammaherpesviruses (GHVs). We hypothesized that proteasome inhibition would induce lytic activation of GHVs and inhibit HIV infectivity via preservation of...
9.
Goldstone S, Lensing S, Stier E, Darragh T, Lee J, van Zante A, et al.
Clin Infect Dis
. 2018 Jul;
68(7):1204-1212.
PMID: 30060087
Background: Anal high-grade squamous intraepithelial lesions (HSILs) ablation may reduce the incidence of invasive cancer, but few data exist on treatment efficacy and natural regression without treatment. Methods: An open-label,...
10.
Ramos J, Sparano J, Rudek M, Moore P, Cesarman E, Reid E, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Feb;
18(3):180-190.e2.
PMID: 29426719
Introduction: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV) or human...